Cagrilintide is under development for the treatment of obesity and type 2 diabetes. The drug candidate is administered as a once-daily and once-weekly subcutaneous formulation. It is a long-acting amylin analogue. Amylin is co-located with insu in secretory granules and co-secreted with insu by pancreatic beta cells in response to food intake.
CagriSema is a combination medication of the GLP-1 receptor agonist semaglutide and cagrilintide. Cagrilinitide mimics the hormone amylin, which is produced by the pancreas. Together with insu, amylin makes people feel satiated or full after eating a meal.
CagriSema is a once-weekly injection of semaglutide and cagrilintide. Phase 2 clinical trial results for CagriSema showed significant improvements in A1C, weight loss, and time in range, marking it as a promising new type 2 diabetes treatment.
Our Promise To You:
Shipping:
1. How can I get one sample before bulk orders?
Yes. Please leave your sample requirements details by email to Biolink sales team. Technical support anytime after-sales.
2. How to preserve peptides after receiving them?
Peptides in the form of lyophilized powder can be transported at room temperature by vacuum packaging, while polypeptides in the dissolved state need to be refrigerated at 2°C - 8°C. For long-term storage, peptides should be stored in the form of lyophilized powder store at -20°C or -80°C in a sealed container with desiccant, which can avoid the degradation of peptides to the greatest extent.
3. What is your payment term?
T/T, Western Union PayPal, and BTC. This is negotiable.
